Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for its Category 1 chemical drug HSK38008 oral preparation has been accepted for review by the National Medical Products Administration (NMPA). Additionally, the NMPA has accepted Haisco’s market filing for its Category 1 chemical HSK7653, according to a separate announcement.
HSK38008: Prostate Cancer Treatment
HSK38008 is the world’s first oral androgen splicing variant degrading agent for the treatment of prostate cancer. The drug degrades the splicing variant of the androgen receptor through the proteasome pathway, blocking the transmission of the androgen receptor signal pathway. This mechanism inhibits the growth and proliferation of prostate cancer cells, positioning HSK38008 as a potential breakthrough therapy in oncology.
HSK7653: Long-Acting DPP-4 Inhibitor
HSK7653 is an in-house developed long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor designed to improve endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) plasma concentrations, thereby enhancing blood sugar control. Previous clinical studies have shown that HSK7653 effectively reduces blood sugar levels without causing gastrointestinal adverse reactions or weight gain. Additionally, the drug does not increase the incidence of hypoglycemia or cardiovascular events and requires no dose adjustment in patients with mild to moderate liver and kidney function impairment.-Fineline Info & Tech
